Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2001-12-14
2004-01-13
Rotman, Alan L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S646000, C514S849000, C560S068000
Reexamination Certificate
active
06677381
ABSTRACT:
FIELD OF THE INVENTION
The invention pertains to guaifenesin tannate and its method of preparation as well as pharmaceutical compositions containing guaifenesin tannate.
BACKGROUND OF THE INVENTION
Guaifenesin is a well-known commercially available compound. It is frequently referred to as guaiphenesin or glyceryl guiacolate. Its chemical name is 3-(2-methoxyphenoxy)-1,2-propanediol. It is a solid having a melting point of 78.5° C., and its molecular formula is C
10
H
14
O
4
. It is only slightly soluble (i.e, about 5 wt. %) in water, but is readily soluble in alcohols such as methanol, ethanol, isopropanol, etc. By way of further identification, its CAS number is 93-14-1.
Guaifenesin finds its principal use as an expectorant for promoting or facilitating the removal of secretions from the respiratory tract in a warm-blooded animal, principally a human being. It helps to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus, drain bronchial tubes and makes coughs more productive. It is typically administered to human beings in need of such medication in the form of tablets and/or suspensions.
Guaifenesin has also proven useful as a central nervous system muscle relaxant for non-human warm-blooded animals, particularly horses and cattle. For animals in need of a muscle relaxant, guaifenesin is typically administered in injectable form.
In recent years, research has indicated that guaifenesin may be useful for alleviation of the symptoms of fibromyalgia syndrome and chronic fatigue syndrome. If such research proves that guaifenesin does in fact alleviate the symptoms of FMS and CFS, it will be a very welcome adjunct in the treatment of these syndromes which are quite painful.
In contradistinction to the antihistamines of which many are unstable in the form of their free bases, guaifenesin is relatively stable. Therefore, little, if any attention, has been paid in recent years to improving guaifenesin compositions. On the other hand, there is a considerable amount of prior art which has emerged in recent years which has been directed to salts of antihistamines, principally tannate salts, which stabilize the antihistamine bases. For example, see U.S. Pat. Nos. 5,599,846; 5,663,415; 6,037,358; 6,287,597; and 6,306,904.
Tannic acid is commercially available and is used in many industrial applications. It is frequently referred to as gallotannic acid, gallotannin; glycerite or tannin. It is a pale tan powder having a decomposition point of 210-215° C., and is highly soluble in water and alcohols. Its molecular formula is C
76
H
52
O
46
; its CAS number is 1401-55-4. Tannic acid is typically produced from Turkish or Chinese nutgall and has a complex non-uniform chemistry and typically contains about 5-10 wt. % water.
As mentioned above, guaifenesin, in contradistinction to the antihistamines, is quite stable and therefor would not require the addition of a material such as tannic acid to render it stable. However, guaifenesin does have one drawback: it is readily absorbed in the patient's body, but its action is relatively short-lived. Indeed, its plasma half-life is only one hour. Accordingly, while it provides relatively quick relief to the patient, the patient is required to take relatively high doses several times a day until the condition which necessitated the administration of the guaifenesin has been alleviated. This presents a particular problem to the patient suffering from chronic bronchitis who is therefore required to be on a constant regimen of guaifenesin, thereby increasing the likelihood of the occurrence of undesirable side effects.
It would be very desirable if a form of guaifenesin was available which would have extended-release properties, i.e., the guaifenesin would be slowly released into the patient's bloodstream over a prolonged period of time. Thus far, the only slow-release forms of guaifenesin which are available are those such as polymer coated tablets. Such prior art formulations provide mixed results in that the guaifenesin is not available for adsorption into the patient's bloodstream until the polymeric coating has been dissolved, but thereafter the guaifenesin is quickly absorbed and metabolized. The result is that frequently, the guaifenesin must again be administered to the patient within the period of only a few hours.
DETAILED DESCRIPTION OF THE INVENTION
It has now been found that it is possible to provide an extended-release form of guaifenesin by reacting it with tannic acid so as to form a novel composition hereinafter referred to as guaifenesin tannate.
The guaifenesin tannate is prepared by a method involving the following steps:
(a) heating guaifenesin to a temperature above its melting point; and
(b) slowly (e.g., over a period of 5-30 minutes) adding tannic acid to the molten guaifenesin, while agitating the reaction mixture.
It is not necessary to have any water or other diluent present during the reaction between the guaifenesin and the tannic acid (indeed, tannic acid itself contains about 5-10 wt. % water). Step (b) is carried out while the guaifenesin is maintained at a temperature in the range of about 80 to about 100° C., preferably 85 to 95° C. After the tannic acid has been added, the reaction mixture is agitated for an additional period of time (10 minutes-2 hours) while maintaining the temperature in the range of about 80 to about 100° C. and the reaction mass is thereafter cooled to room temperature. The solid reaction mass comprising the guaifenesin tannate is preferably thereafter milled to form a free-flowing powder preferably to a particle size of about 50 to about 200 mesh. The molar ratio of the guaifenesin to the tannic acid is in the range of about 3 to about 10, preferably, 4 to 7, moles of guaifenesin per mole of tannic acid. It has been found that using less than 3 moles of guaifenesin per mole of tannic acid results in an incomplete reaction, while the use of more than 10 moles of guaifenesin per mole of tannic acid results in a sticky, hygroscopic reaction mass which is difficult to convert into a free-flowing powder.
It would have been expected that the guaifenesin tannate product resulting from the two step method described above would have the structure of an ester since the reaction involves an alcohol, i.e., guaifenesin which is a diol, and an acid, i.e., tannic acid. It is well known that in the course of a typical esterification reaction, water is formed as a by-product. However, it was found that in the course of the reaction between the guaifenesin and the tannic acid, water was not produced as a by-product. Accordingly, it is believed that the guaifenesin tannate is a complex.
The guaifenesin tannate of the invention has the following physical properties: It has a softening point in the range of 57 to 62° C., in contradistinction to the melting point of 78.5° C. for guaifenesin and 210-215° C. decomposition point for tannic acid.
The guaifenesin tannate of the invention is a light-tan colored powder which is soluble in water and alcohols, but is insoluble in methylene chloride, chloroform or toluene. In contradistinction thereto, guaifenesin is a white powder which is soluble in water, alcohols and methylene chloride and sparingly soluble in toluene, while tannic acid is a tan-colored powder which is soluble in water and alcohols, but is insoluble in methylene chloride, chloroform or toluene. Further proof that the guaifenesin tannate of the present invention is a new material and not a physical mixture of guaifenesin and tannic acid has been obtained by the use of FTIR spectroscopy which is discussed in respect to Examples 1-3 below.
The guaifenesin tannate of the invention may be prepared for oral administration in the form of powders, capsules, elixirs, syrups, etc. Preferably the compositions are prepared in the form of tablets containing about 100 to about 500 mg of guaifenesin tannate of the invention per tablet or as a suspension, i.e., liquid, wherein each 5 ml (teaspoon) of liquid would contain about 100 to about 400 mg of the gu
Chopdekar Vilas M.
Schleck James R.
Jame Fine Chemicals, Inc.
Matalon Jack
Oh Taylor V
Rotman Alan L.
LandOfFree
Guaifenesin tannate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Guaifenesin tannate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Guaifenesin tannate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3214146